Literature DB >> 24627341

When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES.

Jonathan Karnon1, Hossein Haji Ali Afzali.   

Abstract

Modelling in economic evaluation is an unavoidable fact of life. Cohort-based state transition models are most common, though discrete event simulation (DES) is increasingly being used to implement more complex model structures. The benefits of DES relate to the greater flexibility around the implementation and population of complex models, which may provide more accurate or valid estimates of the incremental costs and benefits of alternative health technologies. The costs of DES relate to the time and expertise required to implement and review complex models, when perhaps a simpler model would suffice. The costs are not borne solely by the analyst, but also by reviewers. In particular, modelled economic evaluations are often submitted to support reimbursement decisions for new technologies, for which detailed model reviews are generally undertaken on behalf of the funding body. This paper reports the results from a review of published DES-based economic evaluations. Factors underlying the use of DES were defined, and the characteristics of applied models were considered, to inform options for assessing the potential benefits of DES in relation to each factor. Four broad factors underlying the use of DES were identified: baseline heterogeneity, continuous disease markers, time varying event rates, and the influence of prior events on subsequent event rates. If relevant, individual-level data are available, representation of the four factors is likely to improve model validity, and it is possible to assess the importance of their representation in individual cases. A thorough model performance evaluation is required to overcome the costs of DES from the users' perspective, but few of the reviewed DES models reported such a process. More generally, further direct, empirical comparisons of complex models with simpler models would better inform the benefits of DES to implement more complex models, and the circumstances in which such benefits are most likely.

Entities:  

Mesh:

Year:  2014        PMID: 24627341     DOI: 10.1007/s40273-014-0147-9

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  55 in total

1.  Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.

Authors:  Jonathan Karnon
Journal:  Health Econ       Date:  2003-10       Impact factor: 3.046

2.  Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Authors:  Gerd Laux; Bart Heeg; Ben A van Hout; Angelika Mehnert
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  The cost-effectiveness of atypicals in the UK.

Authors:  Bart Heeg; Erik Buskens; Marc Botteman; Sue Caleo; Mike Ingham; Joep Damen; Frank de Charro; Ben van Hout
Journal:  Value Health       Date:  2008-05-16       Impact factor: 5.725

4.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

5.  Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.

Authors:  Wilma Erhardt; Klas Bergenheim; Isabelle Duprat-Lomon; Phil McEwan
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

6.  A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

Authors:  P M Clarke; A M Gray; A Briggs; A J Farmer; P Fenn; R J Stevens; D R Matthews; I M Stratton; R R Holman
Journal:  Diabetologia       Date:  2004-10-27       Impact factor: 10.122

7.  Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation.

Authors:  Thitima Kongnakorn; Mkaya Mwamburi; Sanjay Merchant; Kasem Akhras; J Jaime Caro; Dilip Nathwani
Journal:  Curr Med Res Opin       Date:  2010-01       Impact factor: 2.580

8.  Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.

Authors:  Alexandra Ward; Duygu Bozkaya; Jochen Fleischmann; Dominique Dubois; Rainer Sabatowski; J Jaime Caro
Journal:  Curr Med Res Opin       Date:  2007-10       Impact factor: 2.580

9.  Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes.

Authors:  R Brett McQueen; Samuel L Ellis; Jonathan D Campbell; Kavita V Nair; Patrick W Sullivan
Journal:  Cost Eff Resour Alloc       Date:  2011-09-14

10.  Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps.

Authors:  Shien Guo; Denis Getsios; Luis Hernandez; Kelly Cho; Elizabeth Lawler; Arman Altincatal; Stephan Lanes; Michael Blankenburg
Journal:  Int J Alzheimers Dis       Date:  2012-12-26
View more
  19 in total

1.  Modelling technique, structural assumptions, input parameter values: which has the most impact on the results of a cost-effectiveness analysis?

Authors:  Josephine Mauskopf
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

2.  Discretely Integrated Condition Event Simulation for Pharmacoeconomics.

Authors:  Mondher Toumi; Ekkehard Beck; Steve Sherman; Leyla Mohseninejad; Samuel Aballéa
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

Review 3.  Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment.

Authors:  Syed Salleh; Praveen Thokala; Alan Brennan; Ruby Hughes; Simon Dixon
Journal:  Pharmacoeconomics       Date:  2017-10       Impact factor: 4.981

4.  Cost-effectiveness of miglustat versus symptomatic therapy of Niemann-Pick disease type C.

Authors:  Medo Gutić; Miloš N Milosavljević; Slobodan M Janković
Journal:  Int J Clin Pharm       Date:  2022-10-15

5.  Operational Modeling with Health Economics to Support Decision Making for COPD Patients.

Authors:  Usame Yakutcan; Eren Demir; John R Hurst; Paul C Taylor; Heidi A Ridsdale
Journal:  Health Serv Res       Date:  2021-03-22       Impact factor: 3.402

6.  Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice.

Authors:  James F O'Mahony; Anthony T Newall; Joost van Rosmalen
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

Review 7.  Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review.

Authors:  Spyros Kolovos; Judith E Bosmans; Heleen Riper; Karine Chevreul; Veerle M H Coupé; Maurits W van Tulder
Journal:  Pharmacoecon Open       Date:  2017-09

8.  Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer.

Authors:  Koen Degeling; Hendrik Koffijberg; Mira D Franken; Miriam Koopman; Maarten J IJzerman
Journal:  Med Decis Making       Date:  2019-01       Impact factor: 2.583

9.  Discrete Event Simulation for Decision Modeling in Health Care: Lessons from Abdominal Aortic Aneurysm Screening.

Authors:  Matthew J Glover; Edmund Jones; Katya L Masconi; Michael J Sweeting; Simon G Thompson
Journal:  Med Decis Making       Date:  2018-04-02       Impact factor: 2.583

10.  Cost-Utility of Internet-Based Cognitive Behavioral Therapy in Unipolar Depression: A Markov Model Simulation.

Authors:  Mathias Baumann; Tom Stargardt; Simon Frey
Journal:  Appl Health Econ Health Policy       Date:  2020-08       Impact factor: 2.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.